Biotech Values

[DewDiligence]

That makes two strikes on RGEN:

By perusing the RGEN board on Yahoo, one can see that a number of investors were hoodwinked into thinking that RGEN and BMY have some kind of collaboration to develop CTLA4. Rereading today’s RGEN PR (#msg-4348920), I surmise that this misconception is by the company’s design rather than by accident.

Was RGEN’s PR unlawful? No. Was it disingenuous? Yes.

This is the second time I’ve encountered questionable behavior by RGEN. The first time was the company’s leaking (through either negligence or malfeasance) of material information about the Secretin trial in autism (#msg-2059119).

Strike two!. One more strike and they’re out, cheap valuation or not.